Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
CureVac

CureVac

A biopharmaceutical company developing prophylactic and therapeutic application of messenger RNA, which can be used to develop vaccines. It was founded in 2000 and is located in Tübingen, Germany.

CureVac is a Germany-based biopharmaceutical company specializing in designing technology that utilizes messenger RNA (mRNA) as a data carrier which is capable of instructing the human body to create proteins to fight viruses, such as COVID-19. The company's technology has been used in multiple medical contexts such as cancer and rare diseases.

Product

The company has both an mRNA platform and production capabilities. Its platform analyzes millions of naturally occurring sequences and houses a nucleotide sequence library where data can be utilized by the CureVac team to created a customized mRNA therapy. The company works in partnerships with other biotechnology entities, such as Lilly, CEPI, and the Bill and Melinda Gates Foundation, to operate its pipeline taking therapeutics from a pre-clinical discovery phase through Phase 2 of clinical trials before finally producing the medical product.

CureVac also produces its mRNA therapies in its own facilities. The company has Good Manufacturing Practices (GMP) and its facilities are capable of producing standardized therapeutics. Industrial manufacturing of products is possible and could be used to produce a vaccine for COVID-19, pending clinical trials.

Timeline

June 30, 2021
CureVac announces appointment of Dr. Malte Greune as Chief Operating Officer and transition of Dr. Florian von der Mülbe to lead accelerated development of The RNA Printer(R)
February 2, 2021
CureVac raises a $450,000,000 venture round.
September 15, 2020
CureVac raises a $306,000,000 grant.
July 21, 2020
CureVac raises a $126,000,000 venture round from Qatar Investment Authority.
July 20, 2020
CureVac raises a $183,000,000 corporate funding round from GlaxoSmithKline.
June 15, 2020
CureVac raises a $458,800,000 venture round.
November 3, 2015
CureVac raises a $29,500,000 series F round from Baillie Gifford and Sigma Capital Group.
November 3, 2015
CureVac raises a $119,633,000 series F round from Baillie Gifford, Bill & Melinda Gates Foundation, Sigma Group and dievini Hopp Biotech Holding.
March 5, 2015
CureVac raises a $76,000,000 series E round from Bill & Melinda Gates Foundation.
September 18, 2012
CureVac raises a $104,432,000 series D round from dievini Hopp Biotech Holding.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

About CureVac

CureVac Receives €80M from EU to Fund Coronavirus Vaccine Amid US Dispute

Jonathan Smith

Web

March 17, 2020

Germany's CureVac Says Low-Dose Coronavirus Vaccine Could Allow for Mass Production

Reuters

Web

March 13, 2020

News

Title
Author
Date
Publisher
Description
Ben Adams
October 12, 2021
FierceBiotech
With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year, and switching focus to its second mRNA asset with GlaxoSmithKline.
Ben Adams
August 16, 2021
FierceBiotech
Back in 2014, a German pharma and a then largely unknown fellow German biotech in CureVac penned a $600 million mRNA cancer pact. Buried in financials posted Monday morning, CureVac quietly reported that Boehringer Ingelheim has walked away from the deal, which was penned in 2014 and included $45 million upfront plus $556 million in biobucks.
Nick Paul
July 1, 2021
FierceBiotech
CureVac has highlighted the efficacy of its failed COVID-19 vaccine in adults aged up to 60 years as evidence the jab has a role to play in the response to the pandemic. The German biotech is pushing ahead with a regulatory submission in Europe despite achieving 48% efficacy in its phase 2b/3 trial.
BioSpace
June 30, 2021
BioSpace
CureVac N.V. today announced the appointment of Dr. Malte Greune as Chief Operating Officer (COO) effective July 1, 2021.
BioSpace
June 23, 2021
BioSpace
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that Dr. Ingmar Hoerr, former Founding-CEO and former member of the Supervisory Board of CureVac, has withdrawn his candidacy for nomination to the Supervisory Board.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.